18th May, 2017, Shanghai, Hong Kong, Boston, San Francisco. Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) jointly announced today a merger to form one healthcare investment group named Dimensions Capital. It will become one of the largest healthcare focused investment firms with an in-depth focus and extensive coverage across China and the US. Dr. Ge Li, the founder, Chairman and CEO of WuXi AppTec, and a Founding Partner of WuXi Healthcare Ventures, will become 6 Dimensions Capital’s Chairman of the Board. Dr. Leon Chen, the Founder and Managing Partner of Frontline BioVentures, will become 6 Dimensions Capital’s CEO. The new investment team will consist of 26 investment professionals, including 9 Partners and 7 Venture Partners.
Forerunner Medical (Shanghai) Co., Ltd. has announced the completion of the acquisition of Shanghai Medsphere Co., Ltd. In addition, the Medtronic-Sequoia China Healthcare Technology Venture Investment Fund (“Medtronic-Sequoia China) has made an investment in Forerunner’s B round financing. Existing Series A investors WuXi Healthcare Ventures (“WXHV”) and Sequoia also participated in the Series B round.
We are pleased to announce that Gregory Verdine, Ph.D., Erving Professor at Harvard University and Harvard Medical School Professor and serial entrepreneur, has joined WuXi Healthcare Ventures (WXHV) as newest Venture Partner.
Dr. Verdine has made numerous important contributions in the translation of bench science to the bedside and has founded, or co-founded, multiple successful biotechnology companies including: Enanta Pharmaceuticals (Nasdaq ENTA), Gloucester Pharmaceuticals (acquired by Celgene), Tokai Pharmaceuticals (Nasdaq TKAI), WaVe Life Sciences (Nasdaq WVE), Eleven Biotherapeutics (Nasdaq EBIO), Warp Drive Bio, Aileron Therapeutics, and FogPharma. He also co-founded the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy.
SHANGHAI and CAMBRIDGE, MA, January 22, 2016 /PRNewswire/ -- -- WuXi Healthcare Ventures (WXHV) announced today that it has joined a $61 million financing round for Twist Bioscience and a $40 million financing round for Syros Pharmaceuticals.
Twist Bioscience has developed an automated semiconductor-based synthetic gene manufacturing process featuring a 10,000-well silicon platformcapable of producing synthetic biology tools, including genes, oligonucleotide pools, and variant libraries. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, this platform enables cost-effective, rapid, high-quality, and high-throughput synthetic gene production and overcomes the current inefficiencies of synthetic DNA production. The Twist platform has the potential to accelerate the application of DNA synthesis in drug development, biofuel and chemical production, agriculture production, biodetection, and data storage. Since its founding in 2013, Twist has raised $133 million in equity and $20 million in debt. WXHV initially invested in Twist’s Series B financing in May 2014.